The biotechnology company focuses on developing therapies that prevent and reverse blindness caused by retinal diseases through a design thinking approach in drug development. By targeting ocular diseases, the company enables physicians to preserve patients' eyesight effectively.
Funding
$40.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Retinal diseases, such as diabetic retinopathy and age-related macular degeneration, can lead to irreversible blindness if not treated promptly. Current treatment options may not always be effective in preventing or reversing vision loss caused by these conditions.
Solution
Osanni Bio is a biotechnology company focused on developing innovative therapies to prevent and reverse blindness resulting from retinal diseases. The company employs a design thinking approach in its drug development process, specifically targeting ocular diseases to enable physicians to effectively preserve patients' eyesight. Their therapeutic strategies aim to address the underlying causes of retinal degeneration, offering potential solutions for patients at risk of vision loss. By focusing on novel mechanisms and delivery methods, Osanni Bio strives to improve outcomes for individuals affected by debilitating eye conditions.
Target Audience
The primary target audience includes ophthalmologists and other physicians treating patients with retinal diseases, as well as patients at risk of vision loss due to these conditions.
Features
- Development of targeted therapies for retinal diseases
- Focus on preventing and reversing blindness
- Utilization of a design thinking approach in drug development